Highest-materiality recent filing
MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials
Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.
MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026
Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.
MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026
Preliminary cash and equivalents ~$450M as of Dec 31, 2025.
MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027
Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.
MapLight Therapeutics prices IPO at $17/sh, raises $296.3M including concurrent private placement
IPO of 14.75M shares at $17.00; underwriters fully exercise option for 2.2125M additional shares.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
Max materiality 0.85 · Median 0.68 · Most common event earnings